Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user (Hospital, Clinical Laboratories) - Global Forecast to 2025

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.2.1             INCLUSIONS & EXCLUSIONS
1.3            MARKET SCOPE
1.3.1             MARKETS COVERED
1.3.2             YEARS CONSIDERED FOR THE STUDY
1.4            CURRENCY
1.5            LIMITATIONS
1.6            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH DATA
2.1.1             SECONDARY DATA
2.1.2             PRIMARY DATA
2.1.3             DATA TRIANGULATION
2.2            MARKET ESTIMATION METHODOLOGY
2.3            MARKET GROWTH RATE PROJECTIONS
2.4            RESEARCH ASSUMPTIONS

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            INFLUENZA DIAGNOSTICS MARKET OVERVIEW.. 26
4.2            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SHARE,
BY TEST TYPE & COUNTRY (2019)
4.3            INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER (2019)

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1             DRIVERS
5.2.1.1           INCREASING PREVALENCE OF INFLUENZA
5.2.1.2           GROWTH IN INFLUENZA RESEARCH
5.2.1.3           RISING DEMAND FOR RAPID DISEASE DIAGNOSIS
5.2.2             RESTRAINTS
5.2.2.1           VARIABILITY IN TEST SENSITIVITY AND SPECIFICITY
5.2.2.2           STRINGENT REGULATORY FRAMEWORK
5.2.2.3           RISING HEALTHCARE COSTS
5.2.3             OPPORTUNITIES
5.2.3.1           ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES
5.2.3.2           SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES
5.2.4             CHALLENGES
5.2.4.1           LACK OF SKILLED PROFESSIONALS
5.3            IMPACT OF COVID-19 OUTBREAK ON THE GROWTH OF
THE INFLUENZA DIAGNOSTICS MARKET
5.3.1             SIMILARITIES IN INFLUENZA AND COVID-19 SYMPTOMS
5.3.2             WHO RECOMMENDATIONS FOR THE CO-TESTING OF COVID-19 & OTHER RESPIRATORY PATHOGENS, INCLUDING INFLUENZA & RSV
5.3.3             INCREASED ADOPTION OF THE INFLUENZA VACCINE (FLU SHOT) IN
THE US HEALTHCARE SYSTEM
5.3.4             INCREASING FOCUS OF DIAGNOSTIC MANUFACTURERS ON THE DEVELOPMENT OF NEW COVID-19 TESTS. 33

6.... INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE

6.1            INTRODUCTION
6.2            TRADITIONAL DIAGNOSTIC TESTS
6.2.1             RIDT
6.2.1.1           RIDT TESTS ARE WIDELY USED OWING TO THEIR EASE OF USE AND RAPID INTERPRETABILITY OF RESULTS
6.2.2             VIRAL CULTURE
6.2.2.1           WIDE USE OF VIRAL CULTURE AS A CONFIRMATORY TEST TO ENSURE THE RESULTS OF RIDT TO DRIVE MARKET GROWTH
6.2.3             DFA
6.2.3.1           ADOPTION OF DFA TESTS IS INCREASING DUE TO THEIR HIGHER SENSITIVITY AS COMPARED TO RIDT
6.2.4             SEROLOGICAL ASSAYS
6.2.4.1           DEVELOPMENT OF LAB-ON-CHIP-BASED MULTIPLEX ASSAYS TO SUPPORT MARKET GROWTH
6.3            MOLECULAR DIAGNOSTIC TESTS
6.3.1             RT-PCR
6.3.1.1           ABILITY OF RT-PCR TO DISTINGUISH BETWEEN INFLUENZA A AND B VIRUSES IS DRIVING ITS ADOPTION IN CLINICAL SETTINGS
6.3.2             ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS
6.3.2.1           TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS
6.3.2.1.1           TMA ACCOUNTS FOR THE LARGEST SHARE OF THE INAAT MARKET
6.3.2.2           LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS
6.3.2.2.1           RAPIDITY, STABILITY, AND SENSITIVITY HAVE DRIVEN THE
USE OF LAMP
6.3.2.3           NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TESTS
6.3.2.3.1           NASBA IS HIGHLY PREFERRED IN HOSPITAL AND CLINICAL
SETTINGS AS IT REDUCES THE NEED FOR ADDITIONAL REVERSE TRANSCRIPTION STEPS
6.3.2.4           OTHER INAAT TESTS
6.3.3             OTHER MOLECULAR TESTS

7.... INFLUENZA DIAGNOSTICS MARKET, BY END USER

7.1            INTRODUCTION
7.2            HOSPITALS
7.2.1             HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
7.3            CLINICAL LABORATORIES
7.3.1             ADVANTAGES OFFERED BY CLINICAL LABORATORIES IN TERMS OF SERVICE COSTS AND TURNAROUND TIME TO SUPPORT MARKET GROWTH
7.4            OTHER END USERS

8.... INFLUENZA DIAGNOSTICS MARKET, BY REGION

8.1            INTRODUCTION
8.2            NORTH AMERICA
8.2.1             US
8.2.1.1           THE US DOMINATED THE NORTH AMERICAN MARKET IN 2019
8.2.2             CANADA
8.2.2.1           GOVERNMENT INITIATIVES AND TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC TECHNIQUES TO SUPPORT MARKET GROWTH
8.3            EUROPE
8.3.1             FRANCE
8.3.1.1           SUPPORTIVE GOVERNMENT POLICIES DRIVE MARKET GROWTH IN FRANCE
8.3.2             UK
8.3.2.1           FREQUENT INFLUENZA OUTBREAKS IN THE UK TO BOOST THE GROWTH OF THE INFLUENZA DIAGNOSTICS MARKET
8.3.3             ROE
8.4            ASIA PACIFIC
8.4.1             INCREASING HEALTHCARE EXPENDITURE AND RISING AWARENESS
INDICATE FAVORABLE PROSPECTS FOR MARKET GROWTH
8.5            REST OF THE WORLD

9.... COMPETITIVE LANDSCAPE

9.1            INTRODUCTION
9.2            MARKET RANKING ANALYSIS, 2019
9.3            COMPETITIVE LEADERSHIP MAPPING
9.3.1             VISIONARY LEADERS
9.3.2             INNOVATORS
9.3.3             DYNAMIC DIFFERENTIATORS
9.3.4             EMERGING COMPANIES
9.4            COMPETITIVE SCENARIO
9.4.1             KEY PRODUCT APPROVALS
9.4.2             KEY ACQUISITIONS. 84

10.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW)*
10.1          F. HOFFMANN-LA ROCHE AG
10.2          QUIDEL CORPORATION
10.3          THERMO FISHER SCIENTIFIC, INC.
10.4          ABBOTT LABORATORIES, INC.
10.5          HOLOGIC, INC.
10.6          BECTON, DICKINSON AND COMPANY
10.7          DANAHER CORPORATION
10.8          DIASORIN SA
10.9          MERIDIAN BIOSCIENCE
10.10        LUMINEX CORPORATION
10.11        BIOMÉRIEUX SA
10.12        GENMARK DIAGNOSTICS, INC.
10.13        SIEMENS HEALTHINEERS
10.14        TECAN TRADING
10.15        SEKISUI DIAGNOSTICS
10.16        SA SCIENTIFIC, LTD.
10.17        ALTONA DIAGNOSTICS GMBH
10.18        CORIS BIOCONCEPT SPRL
10.19        ELITECH GROUP
10.20        MAST GROUP LTD.
* BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
10.21        RIGHT-TO-WIN

11.. APPENDIX

LIST OF TABLES

TABLE 1              INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 2              TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION,
2018–2025 (USD MILLION)
TABLE 3              NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 4              EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 5              ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 6              TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 7              RIDT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 8              NORTH AMERICA: RIDT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 9              EUROPE: RIDT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 10            VIRAL CULTURE MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 11            NORTH AMERICA: VIRAL CULTURE MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 12            EUROPE: VIRAL CULTURE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 13            DFA MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 14            NORTH AMERICA: DFA MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 15            EUROPE: DFA MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 16            SEROLOGICAL ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 17            NORTH AMERICA: SEROLOGICAL ASSAYS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 18            EUROPE: SEROLOGICAL ASSAYS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 19            MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION,
2018–2025 (USD MILLION)
TABLE 20            NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 21            EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 22            ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 23            MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 24            RT-PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 25            NORTH AMERICA: RT-PCR MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 26            EUROPE: RT-PCR MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 27            INAAT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 28            NORTH AMERICA: INAAT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 29            EUROPE: INAAT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 30            INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 31            TMA ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 32            NORTH AMERICA: TMA ASSAYS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 33            LAMP ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 34            NORTH AMERICA: LAMP ASSAYS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 35            NASBA TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 36            NORTH AMERICA: NASBA TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 37            OTHER INAAT TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 38            NORTH AMERICA: OTHER INAAT TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 39            OTHER MOLECULAR TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 40            NORTH AMERICA: OTHER MOLECULAR TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 41            EUROPE: OTHER MOLECULAR TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 42            INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 43            INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION,
2018–2025 (USD MILLION)
TABLE 44            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS,
BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 45            EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 46            INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 47            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 48            EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 49            INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,
2018–2025 (USD MILLION)
TABLE 50            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 51            EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 52            INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 53            INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 54            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 55            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 56            NORTH AMERICA: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 57            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 58            NORTH AMERICA: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 59            NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)
TABLE 60            US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 61            US: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 62            US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 63            US: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 64            US: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION) 65
TABLE 65            CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 66            CANADA: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 67            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 68            CANADA: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 69            CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)
TABLE 70            EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 71            EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 72            EUROPE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 73            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 74            EUROPE: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 75            EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)
TABLE 76            FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 77            FRANCE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 78            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 79            FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)
TABLE 80            UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 81            UK: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82            UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 83            UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION) 72
TABLE 84            ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 85            ROE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 86            ROE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 87            ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)
TABLE 88            ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 89            ASIA PACIFIC: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 90            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 91            ASIA PACIFIC: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 92            ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)
TABLE 93            ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY/REGION,
2018–2025 (USD MILLION)
TABLE 94            CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 95            JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 96            INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 97            ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 98            ROW: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2018–2025 (USD MILLION)
TABLE 99            ROW: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 100          ROW: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 101          ROW: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 102          ROW: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION)

 

FIGURE 1            BREAKDOWN OF PRIMARIES: INFLUENZA DIAGNOSTICS MARKET
FIGURE 2            DATA TRIANGULATION METHODOLOGY
FIGURE 3            MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE-BASED ESTIMATION)
FIGURE 4            MARKET SIZE ESTIMATION: APPROACH 2 (TEST TYPE-BASED ESTIMATION)
FIGURE 5            INFLUENZA DIAGNOSTICS MARKET: CAGR PROJECTIONS
FIGURE 6            INFLUENZA DIAGNOSTICS MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, RESTRAINTS, & CHALLENGES
FIGURE 7            INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2019
FIGURE 8            INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION)
FIGURE 9            GEOGRAPHICAL SNAPSHOT OF THE INFLUENZA DIAGNOSTICS MARKET
FIGURE 10          INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET GROWTH
FIGURE 11          TRADITIONAL DIAGNOSTIC TESTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET IN 2019
FIGURE 12          HOSPITALS DOMINATED THE INFLUENZA DIAGNOSTICS MARKET IN 2019
FIGURE 13          INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES
FIGURE 14          IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE INFLUENZA DIAGNOSTICS MARKET
FIGURE 15          INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
FIGURE 16          PERCENTAGE SHARE OF INFLUENZA SPECIMENS TESTED, BY REGION (2019)
FIGURE 17          NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 18          ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 19          RANK OF COMPANIES IN THE INFLUENZA DIAGNOSTICS MARKET, 2019
FIGURE 20          INFLUENZA DIAGNOSTICS MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 21          F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
FIGURE 22          QUIDEL CORPORATION: COMPANY SNAPSHOT
FIGURE 23          THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
FIGURE 24          ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 25          HOLOGIC, INC.: COMPANY SNAPSHOT
FIGURE 26          BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 27          DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 28          DIASORIN SA: COMPANY SNAPSHOT
FIGURE 29          MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT
FIGURE 30          LUMINEX CORPORATION: COMPANY SNAPSHOT
FIGURE 31          BIOMÉRIEUX SA: COMPANY SNAPSHOT
FIGURE 32          GENMARK DIAGNOSTICS, INC.: COMPANY SNAPSHOT
FIGURE 33          SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
FIGURE 34          TECAN TRADING: COMPANY SNAPSHOT

当レポートのプレスリリースは発行されておりません。